Vanguard Group
FULC icon

Vanguard Group’s Fulcrum Therapeutics FULC Stock Holding History

Vanguard Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40.3M Buy
3,559,552
+560,088
+19% +$5.7M ﹤0.01% 2283
2025
Q3 		$27.6M Sell
2,999,464
-146,979
-5% -$1.06M ﹤0.01% 2459
2025
Q2 		$21.6M Sell
3,146,443
-73,935
-2% -$395K ﹤0.01% 2524
2025
Q1 		$9.27M Sell
3,220,378
-29,229
-0.9% -$107K ﹤0.01% 2889
2024
Q4 		$15.3M Sell
3,249,607
-24,985
-0.8% -$92.2K ﹤0.01% 2727
2024
Q3 		$11.7M Buy
3,274,592
+203,449
+7% +$1.51M ﹤0.01% 2875
2024
Q2 		$19M Buy
3,071,143
+532,478
+21% +$4.03M ﹤0.01% 2601
2024
Q1 		$24M Buy
2,538,665
+18,681
+0.7% +$167K ﹤0.01% 2513
2023
Q4 		$17M Sell
2,519,984
-123,211
-5% -$547K ﹤0.01% 2671
2023
Q3 		$11.7M Buy
2,643,195
+17,166
+0.7% +$75K ﹤0.01% 2791
2023
Q2 		$8.67M Sell
2,626,029
-252,462
-9% -$742K ﹤0.01% 3026
2023
Q1 		$8.2M Buy
2,878,491
+757,868
+36% +$6.79M ﹤0.01% 3051
2022
Q4 		$15.4M Buy
2,120,623
+164,531
+8% +$1.07M ﹤0.01% 2751
2022
Q3 		$15.8M Buy
1,956,092
+426,430
+28% +$3.05M ﹤0.01% 2737
2022
Q2 		$7.5M Buy
1,529,662
+25,841
+2% +$253K ﹤0.01% 3147
2022
Q1 		$35.6M Buy
1,503,821
+35,162
+2% +$498K ﹤0.01% 2473
2021
Q4 		$26M Buy
1,468,659
+215,233
+17% +$4.26M ﹤0.01% 2698
2021
Q3 		$35.4M Buy
1,253,426
+346,391
+38% +$6.56M ﹤0.01% 2550
2021
Q2 		$9.51M Buy
907,035
+63,840
+8% +$645K ﹤0.01% 3233
2021
Q1 		$9.93M Buy
843,195
+181,989
+28% +$2.25M ﹤0.01% 3149
2020
Q4 		$7.74M Buy
661,206
+54,654
+9% +$618K ﹤0.01% 3134
2020
Q3 		$4.81M Buy
606,552
+181,814
+43% +$2.19M ﹤0.01% 3172
2020
Q2 		$7.77M Buy
424,738
+308,821
+266% +$4.86M ﹤0.01% 2889
2020
Q1 		$1.38M Buy
115,917
+42,083
+57% +$673K ﹤0.01% 3405
2019
Q4 		$1.23M Buy
73,834
+57,837
+362% +$553K ﹤0.01% 3584
2019
Q3 		$106K Buy
+15,997
New +$177K ﹤0.01% 4035

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Vanguard Group's FULC Position: Q4 2025 in Review

Vanguard Group increased its Fulcrum Therapeutics (FULC) stake by 19% in Q4 2025, buying an estimated $5.7M and bringing the position to 3,559,552 shares worth $40.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Vanguard Group first reported a position in FULC in Q3 2019 and has held it in 26 quarters since. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • Vanguard Group held 3,559,552 shares of Fulcrum Therapeutics worth $40.3M as of Q4 2025.
  • Vanguard Group bought 560,088 Fulcrum Therapeutics shares in Q4 2025, an estimated $5.7M.
  • Fulcrum Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2283 holding.
  • Vanguard Group first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.